Novartis Eye Drug Works With Fewer Injections Than Rivals

A drug developed by Novartis to treat vision loss in people over 65 does not need to be injected as frequently as a rival medicine from Regeneron to be effective, clinical trials showed on Tuesday.
Reuters Health Information

Full Story →